ValiRx plc (LON:VAL – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 2.94 ($0.04) and traded as low as GBX 2 ($0.03). ValiRx shares last traded at GBX 2.03 ($0.03), with a volume of 263,411 shares trading hands.
ValiRx Stock Performance
The business has a 50 day moving average of GBX 2.40 and a 200-day moving average of GBX 2.94. The company has a market capitalization of £2.68 million, a P/E ratio of -101.25 and a beta of 0.59. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.27 and a current ratio of 2.64.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Featured Stories
- Five stocks we like better than ValiRx
- Best Stocks Under $10.00
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- How to Buy Cheap Stocks Step by Step
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- What is the S&P/TSX Index?
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
